Estados financieros detallados de Enliven Therapeutics, Inc. (ELVN): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Cuenta de Resultados (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Ingresos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | 0 | 0 | $33000 | 0 | 0 | 0 | 0 | 0 | $263000 |
| Beneficio Bruto | 0 | 0 | -$33000 | 0 | 0 | 0 | 0 | 0 | -$263000 |
| I+D | $7.9M | $8.2M | $19.0M | $8.2M | $20.5M | $31.0M | $64.6M | $80.8M | $85.9M |
| Generales y Administrativos | $987000 | $2.4M | $5.1M | $1.1M | $4.3M | $7.8M | $19.0M | $23.8M | $33.8M |
| Gastos Operativos | $8.9M | $10.7M | $24.1M | $9.3M | $24.8M | $38.8M | $83.5M | $104.6M | $119.4M |
| Beneficio Operativo | -$8.9M | -$10.7M | -$24.1M | -$9.3M | -$24.8M | -$38.8M | -$83.5M | -$104.6M | -$119.7M |
| EBITDA | $221000 | -$11.3M | -$23.4M | -$9.3M | -$24.6M | -$37.4M | -$71.3M | -$88.5M | -$103.4M |
| Gastos por Intereses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | $221000 | -$11.3M | -$23.5M | -$19.0M | -$24.7M | -$37.7M | -$71.6M | -$88.8M | -$103.7M |
| Impuestos | $221000 | 0 | 0 | 0 | 0 | 0 | 0 | $232000 | 0 |
| Beneficio Neto | 0 | -$11.3M | -$23.5M | -$19.0M | -$24.7M | -$37.7M | -$71.6M | -$89.0M | -$103.7M |
| BPA | $0.00 | $-2.62 | $-5.43 | $-4.31 | $-3.17 | $-6.03 | $-2.01 | $-1.89 | $-1.83 |
| BPA Diluido | $0.00 | $-2.62 | $-5.43 | $-4.31 | $-3.17 | $-6.03 | $-2.01 | $-1.89 | $-1.83 |
| Acciones en Circulación (Diluidas) | $4.3M | $4.3M | $4.3M | $4.4M | $7.8M | $6.2M | $35.5M | $47.1M | $56.7M |
Cuenta de Resultados (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Ingresos | 0 | 0 | 0 | 0 |
| Beneficio Bruto | 0 | -$46000 | -$14000 | 0 |
| Beneficio Operativo | -$25.1M | -$34.3M | -$27.8M | -$37.2M |
| EBITDA | -$20.1M | -$29.6M | -$23.6M | -$32.5M |
| Beneficio Neto | -$20.1M | -$29.7M | -$23.6M | -$32.5M |
| BPA | $-0.32 | $-0.45 | $-0.38 | $-0.49 |
| BPA Diluido | $-0.32 | $-0.45 | $-0.38 | $-0.49 |
Balance (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Caja y Equivalentes | $9.7M | $7.4M | $4.9M | $47.7M | $110.0M | $75.5M | $100.1M | $124.1M | $98.9M |
| Inversiones a Corto | 0 | 0 | $24.0M | $40.5M | 0 | 0 | $153.0M | $189.3M | $363.7M |
| Cuentas por Cobrar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $10.2M | $7.7M | $30.6M | $90.4M | $110.7M | $77.8M | $266.2M | $318.1M | $474.9M |
| Inmovilizado Material | 0 | 0 | $442000 | $349000 | $954000 | $1.5M | $1.1M | $458000 | $417000 |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $10.2M | $7.7M | $33.3M | $90.8M | $113.3M | $83.3M | $271.9M | $325.8M | $476.2M |
| Cuentas por Pagar | $431000 | $908000 | $1.7M | $2.0M | $2.5M | $3.4M | $532000 | $1.3M | $2.2M |
| Deuda a Corto | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Corrientes | $826000 | $1.8M | $4.2M | $6.2M | $5.8M | $9.7M | $25.9M | $15.9M | $16.6M |
| Deuda a Largo | $660000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Totales | $1.5M | $1.8M | $4.4M | $6.4M | $6.5M | $160.1M | $26.0M | $15.9M | $16.7M |
| Reservas | -$20.0M | -$31.3M | -$54.8M | -$96.1M | -$45.2M | -$82.9M | -$154.4M | -$243.5M | -$347.2M |
| Patrimonio Neto | -$15.5M | -$26.3M | -$48.8M | $84.4M | $106.9M | -$76.8M | $245.9M | $309.8M | $459.6M |
| Deuda Total | $660000 | 0 | 0 | 0 | $159000 | $323000 | $335000 | 0 | $399000 |
| Deuda Neta | -$9.0M | -$7.4M | -$28.9M | -$88.2M | -$109.9M | -$75.2M | -$252.8M | -$313.4M | -$462.2M |
| Capital Circulante | $9.4M | $5.9M | $26.4M | $84.2M | $104.9M | $68.0M | $240.3M | $302.2M | $458.3M |
Balance (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Caja y Equivalentes | $101.7M | $98.9M | $132.2M | $135.5M |
| Activos Totales | $490.9M | $476.2M | $464.9M | $910.2M |
| Pasivos Totales | $14.8M | $16.7M | $11.5M | $15.1M |
| Patrimonio Neto | $476.1M | $459.6M | $453.4M | $895.1M |
| Deuda Total | $387000 | $399000 | $302000 | $1.5M |
Flujo de Caja (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Beneficio Neto | 0 | -$11.3M | -$23.5M | -$19.0M | -$24.7M | -$37.7M | -$71.6M | -$89.0M | -$103.7M |
| Amortizaciones | 0 | 0 | $33000 | $45000 | $115000 | $215000 | $297000 | $317000 | $263000 |
| Compensación en Acciones | 0 | $555000 | $899000 | $130000 | $1.9M | $3.2M | $12.9M | $20.2M | $34.0M |
| Cambio en Capital Circulante | -$188000 | $1.2M | $673000 | $583000 | $3.6M | $438000 | $1.4M | -$4.5M | -$1.1M |
| Flujo de Caja Operativo | -$8.8M | -$8.8M | -$21.9M | -$8.5M | -$19.1M | -$32.1M | -$61.3M | -$73.2M | -$70.3M |
| Inversiones (CapEx) | 0 | 0 | -$140000 | -$461000 | -$191000 | -$612000 | -$149000 | -$44000 | -$158000 |
| Adquisiciones | 0 | 0 | 0 | 0 | 0 | $35.0M | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$8.8M | -$8.8M | -$22.0M | -$9.0M | -$19.3M | -$32.7M | -$61.4M | -$73.2M | -$70.5M |
Flujo de Caja (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Flujo de Caja Operativo | -$13.3M | -$15.8M | -$19.3M | -$18.5M |
| Inversiones (CapEx) | $1000 | 0 | 0 | -$99000 |
| Flujo de Caja Libre | -$13.3M | -$15.8M | -$19.3M | -$18.6M |
| Dividendos Pagados | 0 | 0 | 0 | 0 |
| Compensación en Acciones | $7.2M | $12.3M | $7.4M | $13.9M |
Crecimiento y Márgenes (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Crecimiento Beneficio Neto (anual) | | | -107.0% | +19.2% | -30.4% | -52.2% | -90.1% | -24.4% | -16.5% |
| Crecimiento BPA (anual) | | | -107.3% | +20.6% | +26.5% | -90.2% | +66.7% | +6.0% | +3.2% |
| Cambio en Acciones (anual) | | +0.0% | +0.0% | +1.6% | +78.0% | -20.0% | +468.8% | +32.4% | +20.4% |
| Crecimiento FCF (anual) | | +0.1% | -150.8% | +59.2% | -115.0% | -69.2% | -87.9% | -19.2% | +3.8% |
| Tasa Impositiva Efectiva | 100.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.3% | -0.0% |
Datos por Acción (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| FCF por Acción | $-2.03 | $-2.03 | $-5.10 | $-2.05 | $-2.47 | $-5.23 | $-1.73 | $-1.56 | $-1.24 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $4.3M | $4.3M | $4.3M | $4.4M | $7.8M | $6.2M | $35.5M | $47.1M | $56.7M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Ratios Clave (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| P/E | 0.00 | -22.90 | -11.05 | -20.46 | -2.84 | -2.71 | -6.89 | -11.90 | -8.42 |
| P/VC | -16.69 | -9.85 | -5.31 | 4.59 | 0.66 | -1.33 | 2.00 | 3.42 | 1.90 |
| P/V | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Margen Bruto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Operativo | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Neto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |